3X4 Genetics and Fullscript are expanding their partnership to empower healthcare practitioners with advanced genetic testing and personalized Blueprint Reports, offering a deeper understanding of patients’ unique genetic makeup and enabling tailored treatment plans. This collaboration aims to enhance whole-person care by integrating genetic insights into healthcare decisions, leading to more precise and effective patient outcomes.
GeneDx Holdings (WGS) stock surged over 46% on Tuesday after the genetic testing company reported impressive third-quarter earnings that beat expectations. The company’s revenue skyrocketed, driven by robust growth in exome and genome testing, leading to positive adjusted net income and an optimistic outlook for 2024.
Olivia Munn, 43, was diagnosed with luminal B breast cancer in both breasts last April despite negative genetic testing and clear mammograms. After four surgeries and a hysterectomy, she shares her experience of fighting the disease, the impact on her family, and her hopes for the future. She emphasizes the importance of the Lifetime Risk Test in early detection and encourages women to prioritize their own health. With two healthy embryos frozen, Munn and her partner, John Mulaney, explore the possibility of surrogacy to build their family further.
Labcorp has acquired Invitae Corp’s assets for $239 million in a bankruptcy sale. Invitae filed for bankruptcy protection in February, seeking a sale to continue operations as a going concern. Invitae’s estimated assets ranged from $500 million to $1 billion, while liabilities were significantly higher, between $1 billion and $10 billion.
